CSIRO, Oxitec to Tackle Disease-Spreading Mosquitoes Threatening Mainland Australia

A new venture, Oxitec Australia, is taking on two of the deadliest virus-carrying mosquitos in the Pacific region – Aedes aegypti and Aedes albopictus – to fight the spread of diseases like dengue, Zika, and yellow fever, which claims hundreds of thousands of lives globally each year.

The Asian tiger mosquito (Aedes albopictus) is the most invasive mosquito species in the world. Image Credit: CSIRO

Launched today, Oxitec Australia is a collaboration between CSIRO, Australia’s national science agency, and UK-based Oxitec Ltd, the leading developer of biological solutions to control pests.

The new venture leverages Oxitec's proven biological Friendly platform where genetically engineered male mosquitoes carry a self-limiting gene that ensures only non-biting males survive, reducing pest females and overall mosquito numbers through sustained releases.

Professor Brett Sutton, Director of Health & Biosecurity at CSIRO, said Oxitec Australia is now seeking partners to accelerate its activities and product development in Australia.

Oxitec Australia offers a unique opportunity to help combat the growing threat of invasive and exotic pests, some of which are on mainland Australia’s doorstep like Aedes albopictus,” 

Professor Brett Sutton, Director of Health & Biosecurity, CSIRO

“Factors like climate change and growing pesticide resistance will only bring greater challenges to the health of Australians and our region via vector-borne diseases.

“By investing in new and innovative solutions that complement existing control programs, we can reduce the public health impacts of these exotic and invasive mosquito species.

“This technology platform could also be used to develop solutions for a wide spectrum of pests that threaten livestock and crops and our food systems.”

Subject to government and regulatory approvals, Oxitec Australia’s first solution will be a “just-add-water” product using the Friendly Aedes aegypti mosquito technology.

This innovative product allows for the production of Friendly non-biting male mosquitoes in a short time following the addition of water.

Oxitec Australia is also developing an Aedes albopictus (Asian tiger mosquito) solution, with funding from CSIRO, to help prevent a major invasion risk to mainland Australia.

The new venture is already working with local communities in the Torres Strait affected by this mosquito and dengue outbreaks, with the aim of deploying this technology in impacted regions once completed.

Grey Frandsen, CEO of Oxitec, said the launch of Oxitec Australia is a bold, strategic initiative to combat the region's most pressing invasive pest challenges and is a demonstration of what can be done when innovators come together to solve big challenges.

“In collaboration with Indigenous communities, leading scientific institutions, industry partners and farmers, we’re committed to transforming how pest threats to health, food security and ecosystems are addressed,” Mr Frandsen said.

“In doing so, we aim to not only protect lives, livelihoods and biodiversity, but also empower Indigenous communities to take the lead in addressing their pest challenges." 

Oxitec Australia is also working to address pests threatening crops, such as the fall armyworm caterpillar. First detected in Australia in 2020, this invasive pest can be difficult to control. Oxitec Australia will bring a Friendly fall armyworm product, which is commercially approved in Brazil, with the aim of providing Australian farmers with a targeted solution for this invasive, devastating crop pest.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cancer-Associated Gene MYC Found to Drive Muscle Growth Independently of Exercise